FTC to increase Section 5 scrutiny over ‘Orange Book’ abuses
Pharmaceutical companies that improperly list patents in the Food and Drug Administration’s Orange Book could be in breach of rules that prevent unfair methods of competition, the Federal Trade Commission has said.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10